INCYTE CORP INCY

Latest FY: 2025 Healthcare Biotechnology
Market Price $120.19
Market Cap $24.08B
P/E Ratio 18.75
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑21.2% YoY
$5.14B
3-Yr CAGR: 14.8%
Net Income ↑3,845.0% YoY
$1.29B
Net Margin: 25.0%
Free Cash Flow ↑443.9% YoY
$1.35B
FCF Yield: 5.63%
EPS (Diluted) ↑4,173.3% YoY
$6.41
Basic: $6.59
Return on Equity Efficiency
24.9%
ROA: 404.8%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (INCY)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $1,105.7M $1,047.5M $104.2M $0.54 $304.8M $184.5M
FY 2017 $1,536.2M +38.9% $1,456.7M $-313.1M -400.5% $-1.53 -383.3% $-93.0M $-204.0M -210.6%
FY 2018 $1,881.9M +22.5% $1,787.8M $109.5M +135.0% $0.51 +133.3% $336.2M $262.7M +228.8%
FY 2019 $2,158.8M +14.7% $2,044.5M $446.9M +308.2% $2.05 +302.0% $710.7M $632.6M +140.8%
FY 2020 $2,666.7M +23.5% $2,535.4M $-295.7M -166.2% $-1.36 -166.3% $-124.6M $-312.0M -149.3%
FY 2021 $2,986.3M +12.0% $2,835.3M $948.6M +420.8% $4.27 +414.0% $749.5M $568.5M +282.2%
FY 2022 $3,394.6M +13.7% $3,187.6M $340.7M -64.1% $1.52 -64.4% $969.9M $892.1M +56.9%
FY 2023 $3,695.6M +8.9% $3,440.7M $597.6M +75.4% $2.65 +74.3% $496.5M $464.0M -48.0%
FY 2024 $4,241.2M +14.8% $3,929.1M $32.6M -94.5% $0.15 -94.3% $335.3M $249.1M -46.3%
FY 2025 $5,141.2M +21.2% $4,769.1M $1,286.7M +3,845.0% $6.41 +4,173.3% $1,413.5M $1,354.6M +443.9%
$

Valuation

Market Price $120.19
Market Cap $24.08B
Enterprise Value N/A
P/E Ratio 18.75
P/B Ratio 4.65
FCF Yield 5.63%
Dividend Yield N/A
Shares Outstanding 199,782,200
%

Profitability & Margins

Gross Margin 92.76%
Operating Margin 29.46%
Net Margin 25.03%
Return on Equity (ROE) 24.90%
Return on Assets (ROA) 404.82%
Asset Turnover 16.18x
Revenue 3-Yr CAGR 14.84%
🛡️

Financial Health & Liquidity

Current Ratio 0.31
Cash Ratio 3.00
Debt / Equity N/A
Debt / Assets N/A
Cash & Equivalents $3.10B
Total Debt N/A
Book Value / Share $25.87
💧

Cash Flow Efficiency

Operating Cash Flow $1.41B
Capital Expenditures (CapEx) $58.87M
Free Cash Flow $1.35B
OCF / Revenue 27.49%
FCF / Revenue 26.35%
FCF 3-Yr CAGR 14.94%
🏷️

Per Share Metrics

EPS (Diluted) $6.41
EPS (Basic) $6.59
Dividends / Share N/A
Book Value / Share $25.87
EPS YoY Growth 4,173.33%
🏛️

Balance Sheet (FY 2025)

Total Assets $317.83M
Total Liabilities $1.03B
Stockholders' Equity $5.17B
Current Assets $317.83M
Current Liabilities $1.03B